title: Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C.
abstract: Higher sustained virological response (SVR) rates after treating with peginterferon than after treating with interferon have been obtained in some randomized clinical trials (RCTs) in Chinese patients with chronic hepatitis C (CHC). However, the numbers of patients included in these clinical trials were too small to draw a clear conclusion. Therefore, a new meta-analysis including a large number of patients was needed to compare peginterferon with interferon in the treatment of Chinese CHC patients. A search of Medline, the China National Knowledge Infrastructure, the Wanfang Database, and the China Biomedical Database for relevant articles published between 1966 and 2009 was performed. RCTs comparing the use of peginterferon and interferon for the treatment of Chinese patients with CHC were assessed. Of the 236 studies screened, 18 RCTs including 1,148 patients (659 treated with peginterferon therapy and 489 treated with interferon therapy) were analyzed. The total SVR rates obtained in patients treated with peginterferon were significantly higher than those obtained in patients treated with interferon (64% vs. 40%; relative risk, 1.56; 95% confidence interval: 1.28-1.91; p < 0.01), but the difference between the peginterferon α-2b and interferon α-2b treatments was not significant. Withdrawal rates were similar between patients treated with peginterferon and interferon. Chinese patients with CHC have a greater likelihood of achieving an SVR with peginterferon α-2a.
authors.affiliation: Research Institute of Atherosclerotic Disease, Xi'an Jiaotong University School of Medicine, Shaanxi, China. sihaizhao@mail.xjtu.edu.cn
authors.forename: S
authors.initials: S
authors.lastname: Zhao
authors.forename: E
authors.initials: E
authors.lastname: Liu
authors.forename: K
authors.initials: K
authors.lastname: Wei
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: B
authors.initials: B
authors.lastname: Huang
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: P
authors.initials: P
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002681:China; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014766:Viremia / Q000188:drug therapy; D028761:Withholding Treatment / Q000706:statistics & numerical data; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b
references.citation: Semin Liver Dis. 2003;23 Suppl 1:1-2
references.pmid: 12934161
references.citation: J Infect Dis. 2009 Apr 15;199(8):1112-20
references.pmid: 19284286
references.citation: J Hepatol. 1999 May;30(5):956-61
references.pmid: 10365827
references.citation: J Hepatol. 2002 Oct;37(4):500-6
references.pmid: 12217604
references.citation: Hepatology. 2001 Aug;34(2):395-403
references.pmid: 11481625
references.citation: Aliment Pharmacol Ther. 2004 Nov 1;20(9):931-8
references.pmid: 15521839
references.citation: Am J Med. 2005 Aug;118(8):808-15
references.pmid: 16084169
references.citation: N Engl J Med. 2004 Jul 29;351(5):438-50
references.pmid: 15282351
references.citation: Ann Intern Med. 2004 Mar 2;140(5):346-55
references.pmid: 14996676
references.citation: Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S
references.pmid: 9305658
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Int J Clin Pract. 2009 Sep;63(9):1334-9
references.pmid: 19691617
references.citation: Trends Biotechnol. 1995 Mar;13(3):86-91
references.pmid: 7766222
references.citation: Hepatology. 1999 Sep;30(3):787-93
references.pmid: 10462387
references.citation: Zhonghua Gan Zang Bing Za Zhi. 2007 Mar;15(3):231
references.pmid: 17407724
references.citation: Sidahora. 2002;(4):8-10
references.pmid: 12703472
references.citation: Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2006 Jun;20(2):42-5
references.pmid: 16816861
references.citation: N Engl J Med. 2001 Jul 5;345(1):41-52
references.pmid: 11439948
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: Antivir Chem Chemother. 2004 Nov;15(6):287-97
references.pmid: 15646642
references.citation: J Med Virol. 2001 Nov;65(3):510-6
references.pmid: 11596086
references.citation: Hepatology. 2003 Mar;37(3):590-9
references.pmid: 12601357